Hess J R, Dubick M A, Summary J J, Bangal N R, Wade C E
Division of Military Trauma Research, Letterman Army Institute of Research, Presidio of San Francisco, CA 94129.
J Trauma. 1992 Jan;32(1):40-4. doi: 10.1097/00005373-199201000-00009.
The combination solution of 7.5% NaCl/6% dextran 70 (HSD) administered IV gives hemodynamic improvement in the treatment of hemorrhagic hypotension. Since earlier dextran solutions were reported to interfere with blood coagulation, the effects of HSD on the prothrombin time (PT), the activated partial thromboplastin time (APTT), platelet aggregation, and platelet concentration were studied. The HSD mixed with human plasma (1:5 and 1:10) slightly prolonged PT, but had no effect on the APTT, compared with saline controls. The HSD also decreased human platelet aggregation at the 1:5 dilution. In separate mixing studies, the hypertonic saline component of HSD was associated with the prolongation of PT and decreased platelet aggregation. The data from these studies indicate that at its proposed therapeutic dose, HSD is expected to have minimal effect on blood coagulation.
静脉注射7.5%氯化钠/6%右旋糖酐70（HSD）的联合溶液在治疗出血性低血压时可改善血流动力学。由于早期有报道称右旋糖酐溶液会干扰血液凝固，因此研究了HSD对凝血酶原时间（PT）、活化部分凝血活酶时间（APTT）、血小板聚集和血小板浓度的影响。与生理盐水对照组相比，HSD与人血浆按1:5和1:1混合时可轻微延长PT，但对APTT无影响。HSD在1:5稀释度时也可降低人血小板聚集。在单独的混合研究中，HSD的高渗盐水成分与PT延长和血小板聚集降低有关。这些研究数据表明，在建议的治疗剂量下，HSD预计对血液凝固的影响最小。
